Assay

Protein Labeling Market Size Worth $4.11 Billion By 2030: Grand View Research, Inc.

Retrieved on: 
Monday, June 13, 2022

SAN FRANCISCO, June 13, 2022 /PRNewswire/ --The global protein labeling market size is expected to reach USD 4.11 billion by 2030, according to a new report by Grand View Research, Inc.

Key Points: 
  • SAN FRANCISCO, June 13, 2022 /PRNewswire/ --The global protein labeling market size is expected to reach USD 4.11 billion by 2030, according to a new report by Grand View Research, Inc.
  • One such development includes the application of new spin labels that expand the capability of site-directed spin labeling of proteins.
  • Get more Insights from 130 page market research report, " Protein Labeling Market Size, Share & Trends Analysis Report By Product (Services, Kits, Reagents), By Application (Fluorescence Microscopy, Cell-based Assays), By Method (In-vitro, In-vivo), And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the global protein labeling market on the basis of product, application, method, and region:
    Protein Labeling Market- Product Outlook (Revenue, USD Million, 2018 - 2030)

Global Non-Animal Alternative Testing Market Predicted to Hit $29,390.20 Million, Growing at 13.0% CAGR from 2021 to 2030 [290-Pages] | Proclaimed by Research Dive

Retrieved on: 
Friday, June 10, 2022

NEW YORK, June 10, 2022 /PRNewswire/ -- Research Dive has added a new report to its offerings titled, "Non-animal alternative testing Testing Market by Technology (Cell Culture Technology, High Throughput Technology, Molecular Imaging, and Omic Technology), Method (Cellular Assay, Biochemical Assay, In Silico, and Ex-vivo), End-user (Pharmaceutical Industry, Cosmetics & Household Products, Diagnostics, Chemical Industry, and Food Industry), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021-2030".

Key Points: 
  • The rising need for animal cruelty-free drug development testing methods is fueling the global non-animal alternative testing market growth.
  • The global non-animal alternative testing market is expected to garner $29,390.20 million by 2030, growing at a CAGR of 13.0% from 2021 to 2030.
  • Key Segment Findings of the Non-Animal Alternative Testing Market:
    The market is segmented based on technology, method, end-user, and region.
  • As a result, the demand for non-animal alternative testing has greatly surged; which is fueling the non-animal alternative testing market growth amidst the pandemic period.

Global Non-Animal Alternative Testing Market Predicted to Hit $29,390.20 Million, Growing at 13.0% CAGR from 2021 to 2030 [290-Pages] | Proclaimed by Research Dive

Retrieved on: 
Friday, June 10, 2022

NEW YORK, June 10, 2022 /PRNewswire/ -- Research Dive has added a new report to its offerings titled, "Non-animal alternative testing Testing Market by Technology (Cell Culture Technology, High Throughput Technology, Molecular Imaging, and Omic Technology), Method (Cellular Assay, Biochemical Assay, In Silico, and Ex-vivo), End-user (Pharmaceutical Industry, Cosmetics & Household Products, Diagnostics, Chemical Industry, and Food Industry), and Regional Analysis (North America, Europe, Asia-Pacific, and LAMEA): Global Opportunity Analysis and Industry Forecast, 2021-2030".

Key Points: 
  • The rising need for animal cruelty-free drug development testing methods is fueling the global non-animal alternative testing market growth.
  • The global non-animal alternative testing market is expected to garner $29,390.20 million by 2030, growing at a CAGR of 13.0% from 2021 to 2030.
  • Key Segment Findings of the Non-Animal Alternative Testing Market:
    The market is segmented based on technology, method, end-user, and region.
  • As a result, the demand for non-animal alternative testing has greatly surged; which is fueling the non-animal alternative testing market growth amidst the pandemic period.

Malaria breakthrough: A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite

Retrieved on: 
Wednesday, June 8, 2022

This result therefore paves the way to wider screens to identify even better compounds against parasite transmission."

Key Points: 
  • This result therefore paves the way to wider screens to identify even better compounds against parasite transmission."
  • CNR - National Research Council, is a national research public institution with multidisciplinary proficiency, supervised by the Ministry of Education, University and Research (MUR).
  • IRBM is a drug hunting company workingacross all aspects of drug discovery and early development for different modalities small molecule, peptides, and antibodies.
  • IRBM's scientists have discovered several drugs that are on the market, and more than 25 compounds have gone into clinical testing.

Malaria breakthrough: A collaboration between ISS, IRBM and CNR has led to the discovery of new molecules blocking the transmission of the parasite

Retrieved on: 
Wednesday, June 8, 2022

This result therefore paves the way to wider screens to identify even better compounds against parasite transmission."

Key Points: 
  • This result therefore paves the way to wider screens to identify even better compounds against parasite transmission."
  • CNR - National Research Council, is a national research public institution with multidisciplinary proficiency, supervised by the Ministry of Education, University and Research (MUR).
  • IRBM is a drug hunting company workingacross all aspects of drug discovery and early development for different modalities small molecule, peptides, and antibodies.
  • IRBM's scientists have discovered several drugs that are on the market, and more than 25 compounds have gone into clinical testing.

Bioanalytical Testing Services Market Global Forecast to 2027: Growing Demand for Specialized Bioanalytical Testing Services in Developing Economies - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 26, 2022

The "Bioanalytical Testing Services Market Research Report by Type, Application, End User, Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bioanalytical Testing Services Market Research Report by Type, Application, End User, Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • This report categorizes the Bioanalytical Testing Services to forecast the revenues and analyze the trends in each of the following sub-markets:
    Based on Type, the market was studied across Biomarker Testing, Cell-Based Assays, Method Development Optimization & Validation, Pharmacokinetic Testing, Serology, Immunogenicity, & Neutralizing Antibodies, and Virology Testing.
  • The Virology Testing is further studied across In Vitro Virology Testing, In Vivo Virology Testing, and Species-Specific Viral PCR Assays.
  • Based on End User, the market was studied across Contract Development & Manufacturing Organizations, Contract Research Organizations, and Pharmaceutical & Biopharmaceutical Companies.

Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022

Retrieved on: 
Thursday, May 19, 2022

PARIS, May 19, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that it will present for the first time proof-of-concept data from clinical trials with EO2401, its first-in-class off-the-shelf OncoMimics™ cancer immunotherapy at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually. 

Key Points: 
  • To-date, Enterome has generated a repertoire of OncoMimics peptides correlating to tumor antigens across a wide range of solid and liquid tumor types.
  • From this, the Company is creating a pipeline of off-the-shelf cancer immunotherapies designed to act via the same novel mode of action.
  • EO2463 combines four OncoMimics peptides that exhibit molecular mimicry with the B cell markers CD20, CD22, CD37, and CD268 (BAFF-receptor), respectively.
  • "We are thrilled to be able to present the first clinical data demonstrating the potential of our unique OncoMimics pipeline at ASCO this year.

Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022

Retrieved on: 
Thursday, May 19, 2022

PARIS, May 19, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces that it will present for the first time proof-of-concept data from clinical trials with EO2401, its first-in-class off-the-shelf OncoMimics™ cancer immunotherapy at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7, 2022 in Chicago and virtually. 

Key Points: 
  • To-date, Enterome has generated a repertoire of OncoMimics peptides correlating to tumor antigens across a wide range of solid and liquid tumor types.
  • From this, the Company is creating a pipeline of off-the-shelf cancer immunotherapies designed to act via the same novel mode of action.
  • EO2463 combines four OncoMimics peptides that exhibit molecular mimicry with the B cell markers CD20, CD22, CD37, and CD268 (BAFF-receptor), respectively.
  • "We are thrilled to be able to present the first clinical data demonstrating the potential of our unique OncoMimics pipeline at ASCO this year.

Measuring endocrine disruptors in wastewater

Retrieved on: 
Tuesday, April 12, 2022

QUBEC and MONTRAL, April 12, 2022 /CNW Telbec/ - Treating pollutants, such as endocrine disruptors, is an effective way to protect the environment.

Key Points: 
  • QUBEC and MONTRAL, April 12, 2022 /CNW Telbec/ - Treating pollutants, such as endocrine disruptors, is an effective way to protect the environment.
  • Endocrine disruptors are chemicals that alter the hormonal systems and the development of organisms that are exposed to them, even in small quantities.
  • "There is interest in Qubec and around the world in finding ways to track endocrine disruptors.
  • The challenge in monitoring wastewater comes from the "cocktail" of endocrine disruptors it contains.

Clayton Pharmaceuticals and VistaPharm (a Vertice company) Receive FDA Approval for Sucralfate Oral Suspension

Retrieved on: 
Thursday, April 7, 2022

EXTON, Pa. , April 7, 2022 /PRNewswire/ -- Clayton Pharmaceuticals, a thought leader and pioneer in developing innovative pathways to establish bioequivalence for complex generic drug products, announces that they have received FDA approval for Sucralfate Oral Suspension with Competitive Generic Therapy (CGT) designation.

Key Points: 
  • EXTON, Pa., April 7, 2022 /PRNewswire/ -- Clayton Pharmaceuticals, a thought leader and pioneer in developing innovative pathways to establish bioequivalence for complex generic drug products, announces that they have received FDA approval for Sucralfate Oral Suspension with Competitive Generic Therapy (CGT) designation.
  • Dr. Sid Bhoopathy, the President and CEO of Clayton Pharmaceuticals, commented "This ANDA approval using welldesigned, scientifically sound in vitro bioassays endorses the use of novel approaches to demonstrate product bioequivalence.
  • Scott Meyers, CEO of Vertice, shared "I am proud that the strong collaboration between our companies has resulted in an FDA approval for Sucralfate Oral Suspension.
  • Congratulations also for the outstanding operational execution that resulted in us quickly receiving CGT designation for this product following FDA approval."